News headlines about Flamel Technologies (NASDAQ:AVDL) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Flamel Technologies earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.4388015261671 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern’s rankings:

Flamel Technologies (NASDAQ:AVDL) traded down 2.12% during midday trading on Monday, reaching $9.22. The company’s stock had a trading volume of 136,123 shares. The firm has a 50 day moving average price of $9.03 and a 200 day moving average price of $9.82. Flamel Technologies has a 1-year low of $8.14 and a 1-year high of $14.15. The firm has a market capitalization of $369.57 million, a PE ratio of 9.74 and a beta of 1.39.

Flamel Technologies (NASDAQ:AVDL) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.14. Flamel Technologies had a return on equity of 29.84% and a net margin of 21.13%. The firm had revenue of $46.30 million for the quarter, compared to analysts’ expectations of $45.17 million. Flamel Technologies’s revenue for the quarter was up 19.0% compared to the same quarter last year. On average, analysts predict that Flamel Technologies will post $1.16 EPS for the current year.

A number of equities research analysts have issued reports on AVDL shares. Zacks Investment Research upgraded Flamel Technologies from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Monday, July 17th. Roth Capital set a $15.00 target price on Flamel Technologies and gave the company a “buy” rating in a research note on Wednesday, August 9th. Ladenburg Thalmann Financial Services raised their target price on Flamel Technologies from $27.00 to $30.00 in a research note on Thursday, September 7th. Finally, Langenberg & Company reiterated a “buy” rating and issued a $30.00 target price (up from $27.00) on shares of Flamel Technologies in a research note on Thursday, September 7th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Flamel Technologies currently has a consensus rating of “Buy” and a consensus target price of $19.83.

ILLEGAL ACTIVITY NOTICE: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at

In other Flamel Technologies news, major shareholder Healthcare Master Fun Broadfin sold 261,000 shares of the business’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $10.68, for a total value of $2,787,480.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Craig R. Stapleton acquired 20,000 shares of Flamel Technologies stock in a transaction on Tuesday, September 12th. The stock was acquired at an average cost of $9.52 per share, for a total transaction of $190,400.00. Following the purchase, the director now owns 507,678 shares of the company’s stock, valued at approximately $4,833,094.56. The disclosure for this purchase can be found here. Insiders acquired 41,700 shares of company stock worth $394,848 over the last quarter. Company insiders own 5.07% of the company’s stock.

Flamel Technologies Company Profile

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Insider Buying and Selling by Quarter for Flamel Technologies (NASDAQ:AVDL)

Receive News & Stock Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related stocks with our FREE daily email newsletter.